Meta-analysis of the efficacy and safety of bortezomib Re-treatment in patients with multiple myeloma

Clinical Lymphoma, Myeloma and Leukemia

Volumn 14, Issue 5, 2014, Pages 380-388

  Knopf, Kevin B ^a   Duh, Mei Sheng ^b   Lafeuille, Marie Hélène ^c   Gravel, Jonathan ^c   Lefebvre, Patrick ^c   Niculescu, Liviu ^d   Ba Mancini, Abbie ^d   Ma, Esprit ^d   Shi, Hongliang ^d   Comenzo, Raymond L ^e  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b ANALYSIS GROUP   (United States)

^c Groupe conseil   (Canada)

^d MILLENNIUM PHARMACEUTICALS INC   (United States)

^e TUFTS MEDICAL CENTER   (United States)

Author keywords

Meta regression analysis; Overall response rate; Random effect model; Refractory; Relapsed

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE; TUMOR PROTEIN;

ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE COURSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; KIDNEY FAILURE; META ANALYSIS; MULTIPLE MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; RETREATMENT; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; ENZYMOLOGY; HEMATOLOGIC DISEASE; MOLECULARLY TARGETED THERAPY; RECURRENT DISEASE; RETROSPECTIVE STUDY; SALVAGE THERAPY; SURVIVAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; HEMATOLOGIC DISEASES; HUMANS; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PERIPHERAL NERVOUS SYSTEM DISEASES; PNEUMONIA; PROTEASOME INHIBITORS; PYRAZINES; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84908660486     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2014.03.005     Document Type: Article

References (50)

1. A. Palumbo, and K. Anderson Multiple myeloma N Engl J Med 364 2011 1046 1060
2. K.C. Anderson, M. Alsina, and W. Bensinger Multiple myeloma J Natl Compr Canc Netw 9 2011 1146 1183
3. A. Jakubowiak Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives Semin Hematol 49 suppl 1 2012 S16 32
4. P. Moreau The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies Semin Hematol 49 suppl 1 2012 S33 46
5. B. Mohty, J. El-Cheikh, and I. Yakoub-Agha Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents Leukemia 26 2012 73 85
6. National Comprehensive Cancer Network Inc. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Multiple myeloma. Version 1.2014. Available at: http://www.nccn.org/professionals/physician-gls/pdf/myeloma.pdf. Accessed October 18, 2013.
7. P. Moreau, P.G. Richardson, and M. Cavo Proteasome inhibitors in multiple myeloma: 10 years later Blood 120 2012 947 959
8. P.G. Richardson, P. Sonneveld, and M.W. Schuster Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med 352 2005 2487 2498
9. P. Moreau, H. Pylypenko, and S. Grosicki Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study Lancet Oncol 12 2011 431 440
10. R. Niesvizky, P.G. Richardson, and S.V. Rajkumar The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma Br J Haematol 143 2008 46 53
11. T.M. Conner, Q.D. Doan, and I.B. Walters An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma Clin Lymphoma Myeloma 8 2008 140 145
12. I. Hrusovsky, B. Emmerich, and A. von Rohr Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland Oncology 79 2010 247 254
13. M.T. Petrucci, P. Giraldo, and P. Corradini A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma Br J Haematol 160 2013 649 659
14. R. Sood, H. Carloss, and R. Kerr Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib Am J Hematol 84 2009 657 660
15. C. Taverna, J. Voegeli, and A. Trojan Effective response with bortezomib retreatment in relapsed multiple myeloma-a multicentre retrospective survey in Switzerland Swiss Med Wkly 142 2012 w13562
16. J. Wolf, P.G. Richardson, and M. Schuster Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series Clin Adv Hematol Oncol 6 2008 755 760
17. M. Alsina, R.L. Schlossman, and D.M. Weber PANORAMA 2: a phase II study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma J Clin Oncol 30 suppl 2012 8012 (abstract 8012)
18. J.R. Berenson, S. Jagannath, and B. Barlogie Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma Cancer 104 2005 2141 2148
19. J.R. Berenson, O. Yellin, and T. Kazamel A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma Leukemia 26 2012 1675 1680
20. A. Canovas, J.J. Alonso, and B. Barreiro Bortezomib retreatment in relapsed or refractory multiple myeloma: results in a cohort of 52 patients Haematologica 94 suppl 2 2009 617-8 (abstract 1601)
21. S. Ciolli, F. Leoni, and C. Casini Feasibility and efficacy of bortezomib re-treatment in multiple myeloma Haematologica 92 suppl 1 2007 95 (abstract 0260)
22. I.M. Ghobrial, E. Weller, and R. Vij Final results of the phase I/II trial of weekly bortezomib in combination with temsirolimus (CCI-779) in relapsed or relapsed/refractory multiple myeloma specifically in patients refractory to bortezomib Blood 116 2010 435-6 (abstract 990)
23. A.J. Jakubowiak, D.M. Benson, and W. Bensinger Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma J Clin Oncol 30 2012 1960 1965
24. J.O. Lee, S.M. Bang, and J. Hong A multicenter retrospective analysis of retreatment with bortezomib for multiple myeloma: results of the Korean Multiple Myeloma Working Party (KMMWP) Haematologica 96 suppl 1 2011 S166-7 (abstract A-464)
25. H. Ludwig, H. Kaspanu, and H. Gisslinger Bortezomib-bendamustine-dexamethasone for treatment of relapsed/refractory myeloma Haematologica 96 suppl 2 2011 127 (abstract 0305)
26. A. Mazumder, D.H. Vesole, and S. Jagannath Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice Clin Lymphoma Myeloma Leuk 10 2010 149 151
27. P. Musto, A. Falcone, and G. Sanpaolo Re-treatment with bortezomib in multiple myeloma Haematologica 91 suppl 1 2006 438 (abstract 1213)
28. P.G. Richardson, A.Z. Badros, and S. Jagannath Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma Br J Haematol 150 2010 428 437
29. P.G. Richardson, J. Wolf, and A. Jakubowiak Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial J Clin Oncol 29 2011 4243 4249
30. P.G. Richardson, A.A. Chanan-Khan, and S. Lonial Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study Br J Haematol 153 2011 729 740
31. A. Rubio-Martinez, V. Recasens, and B. Soria Response to re-treatment on relapsed multiple myeloma patients previously treated with bortezomib Haematologica 93 suppl 1 2008 261 (abstract 0649)
32. D.S. Siegel, M.A. Dimopoulos, and S.S. Yoon Vantage 095: vorinostat in combination with bortezomib in salvage multiple myeloma patients: final study results of a global phase 2b trial Blood 118 2011 223 224 (abstract 480)
33. N. Skvortsova, T. Pospelova, and I. Nechunaeva Antitumor activity of bortezomib retreatment in relapsed or refractory multiple myeloma patients Haematologica 95 suppl 2 2010 590 (abstract 1481)
34. M.T. Petrucci, I.W. Blau, and P. Corradini Efficacy and safety of retreatment with bortezomib in patients with multiple myeloma: interim results from RETRIEVE, a prospective international phase 2 study Haematologica 95 suppl 2 2010 152 (abstract 0372)
35. P.G. Richardson, P. Sonneveld, and M. Schuster Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial Blood 110 2007 3557 3560
36. B. Arnulf, H. Pylypenko, and S. Grosicki Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma Haematologica 97 2012 1925 1928
37. I.M. Ghobrial, E. Weller, and R. Vij Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study Lancet Oncol 12 2011 263 272
38. S.K. Kumar, J.H. Lee, and J.J. Lahuerta Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study Leukemia 26 2012 149 157
39. S.K. Kumar, T.M. Therneau, and M.A. Gertz Clinical course of patients with relapsed multiple myeloma Mayo Clin Proc 79 2004 867 874
40. D.S. Siegel, T. Martin, and M. Wang A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma Blood 120 2012 2817 2825
41. D.S. Siegel, T. Martin, and S. Singhal Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1 J Clin Oncol 30 suppl 2012 8035 (abstract 8035)
42. R. Vij, P.G. Richardson, and S. Jagannath Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT) J Clin Oncol 30 suppl 2012 8016 (abstract 8016)
43. M. Delforge, A. Michiels, and C. Doyen Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium Acta Clin Belg 66 2011 371 375
44. H. Avet-Loiseau, J. Soulier, and J.P. Fermand Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone Leukemia 24 2010 623 628
45. J.F. San Miguel, R. Schlag, and N.K. Khuageva Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma J Clin Oncol 31 2013 448 455
46. R.Z. Orlowski, A. Nagler, and P. Sonneveld Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression J Clin Oncol 25 2007 3892 3901
47. M.A. Dimopoulos, M.V. Mateos, and P.G. Richardson Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study Eur J Haematol 86 2011 23 31
48. P.G. Richardson, P. Sonneveld, and M.W. Schuster Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline Br J Haematol 144 2009 895 903
49. P. Sonneveld, I.G. Schmidt-Wolf, and B. van der Holt Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial J Clin Oncol 30 2012 2946 2955
50. M.V. Mateos, A. Oriol, and J. Martinez-Lopez Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial Blood 120 2012 2581 2588